Who we do it for

The UK government set an ambitious goal of eliminating hepatitis C by 2023 – a goal even more ambitious than the World Health Organization’s deadline of 2030. As a leading provider of effective treatment for hepatitis C, our client knew that the time is now to push forward and reach this goal.

Our client wanted to create a regular touchpoint with ophthalmologists to provide peer-to-peer education and discussion on hot topics. As a leader in the therapy area, the client wanted to be seen as a trusted partner and forge long-term relationships with a KOL faculty pool and the wider medical community. Is that your goal too?

We have been working with a client for several years to create engaging content for their medical education brand across four neuroscience therapeutic areas. This is a continual evolution and Jango is pivotal in developing new educational content in a variety of formats. How do you ensure your educational offerings stay exciting and current?

The digital revolution has happened and COVID confirmed the need for effective communication outside face-to-face interactions. Our client wanted to enable their medical scientific liaison (MSL) team to follow up with medical experts after calls in a personalised and tailored way, while also being compliant with all the necessary regulations. How would you balance these two factors?

Our client wanted to rationalise, refresh and update their internal training resources. When did you last take a critical look at your internal materials?

Our client was chatting to a leading dermatologist when he mentioned that he and his colleagues often struggle to know what to do about the psychological impact of skin conditions.

We were briefed to organise, attend and write up an advisory board meeting to discuss a pre-launch product and how it would fit in the treatment landscape. The client wanted to use the advice to inform it’s regulatory approval submission. How often have you put out such a brief?

Our client’s ophthalmology product was effective, trusted and established, but not being used early enough in the patient pathway. Sound familiar? The strategic goal was to focus on switch opportunities in a crowded market, and help clinicians recognise the patients for whom our client’s product should be an early switch consideration. Which tactic would you choose?